Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more
Sartorius Stedim Biotech S.A (SDMHF) - Total Liabilities
Latest total liabilities as of December 2025: $3.89 Billion USD
Based on the latest financial reports, Sartorius Stedim Biotech S.A (SDMHF) has total liabilities worth $3.89 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sartorius Stedim Biotech S.A - Total Liabilities Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sartorius Stedim Biotech S.A Competitors by Total Liabilities
The table below lists competitors of Sartorius Stedim Biotech S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Haid Group Co Ltd
SHE:002311
|
China | CN¥24.28 Billion |
|
PT Astra International Tbk
PINK:PTAIF
|
USA | $209.04 Trillion |
|
F.N.B. Corp
NYSE:FNB
|
USA | $43.47 Billion |
|
MGIC Investment Corp
NYSE:MTG
|
USA | $1.49 Billion |
|
China Oilfield Services Ltd Class A
SHG:601808
|
China | CN¥37.13 Billion |
|
Churchill Downs Incorporated
NASDAQ:CHDN
|
USA | $6.43 Billion |
|
Amkor Technology Inc
NASDAQ:AMKR
|
USA | $3.63 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Sartorius Stedim Biotech S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sartorius Stedim Biotech S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sartorius Stedim Biotech S.A (2005–2025)
The table below shows the annual total liabilities of Sartorius Stedim Biotech S.A from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.89 Billion | -8.10% |
| 2024-12-31 | $4.23 Billion | -16.46% |
| 2023-12-31 | $5.07 Billion | +98.60% |
| 2022-12-31 | $2.55 Billion | +15.03% |
| 2021-12-31 | $2.22 Billion | +39.80% |
| 2020-12-31 | $1.59 Billion | +146.80% |
| 2019-12-31 | $642.79 Million | +22.07% |
| 2018-12-31 | $526.59 Million | +0.41% |
| 2017-12-31 | $524.45 Million | +21.32% |
| 2016-12-31 | $432.29 Million | +3.19% |
| 2015-12-31 | $418.92 Million | +13.76% |
| 2014-12-31 | $368.25 Million | -5.43% |
| 2013-12-31 | $389.39 Million | +8.42% |
| 2012-12-31 | $359.14 Million | +10.49% |
| 2011-12-31 | $325.04 Million | +11.59% |
| 2010-12-31 | $291.27 Million | +6.05% |
| 2009-12-31 | $274.66 Million | -2.15% |
| 2008-12-31 | $280.70 Million | +0.98% |
| 2007-12-31 | $277.96 Million | +33.37% |
| 2006-12-31 | $208.41 Million | -2.69% |
| 2005-12-31 | $214.18 Million | -- |